A new methodology for cost-effectiveness studies of domestic radon remediation programmes: Quality-adjusted life-years gained within Primary Care Trusts in Central England

Science of the Total Environment

Volumn 366, Issue 1, 2006, Pages 32-46

  Coskeran, Thomas ^a   Denman, Antony ^b   Phillips, Paul ^c   Gillmore, Gavin ^d   Tornberg, Roger ^e  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NORTHAMPTON   (United Kingdom)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

^e Radon Centres Ltd   (United Kingdom)

Author keywords

Cost effectiveness; Lung cancer; Primary Care Trusts; Radon remediation

Indexed keywords

BIOLOGICAL RADIATION EFFECTS; COST EFFECTIVENESS; HEALTH CARE; HEALTH RISKS; RADIOACTIVE ELEMENTS; TUMORS;

LUNG CANCER; PRIMARY CARE TRUSTS; RADON REMEDIATION; REMEDIATION PROGRAMMES;

REMEDIATION;

RADON;

COST-BENEFIT ANALYSIS; ENVIRONMENTAL ECONOMICS; INDOOR RADON; RADIOACTIVE POLLUTION; REMEDIATION;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH PROGRAM; HOUSEHOLD; POLLUTION CONTROL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTECTION; QUALITY ADJUSTED LIFE YEAR; RADIATION; RADIOACTIVE CONTAMINATION; UNITED KINGDOM;

AIR POLLUTION, RADIOACTIVE; COST-BENEFIT ANALYSIS; ENGLAND; ENVIRONMENTAL EXPOSURE; GEOGRAPHY; HOUSING; HUMANS; LUNG NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PREVENTIVE HEALTH SERVICES; RADON;

ENGLAND; EURASIA; EUROPE; NORTHAMPTONSHIRE; OXFORDSHIRE; UNITED KINGDOM; WESTERN EUROPE;

EID: 33745820007     PISSN: 00489697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2005.12.020     Document Type: Article

References (54)

1. Abelson P. Radon today: the role of flimflam in public policy. Regulation 14 4 (1991) 95-100
2. Allsup S., Haycox A., Regan M., and Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years?: a randomised controlled trial. Vaccine 23 5 (2004) 639-645
3. Baker R., Chilton S., Donaldson C., Jones-Lee M., Metcalf H., Shackley P., et al. Determining the societal value of a QALY by surveying the public in England and Wales: a research protocol. Submission to National Institute for Clinical Excellence and National Coordinating Centre for Research Methodology (2003)
4. Baldwin G., Frank E., and Fielding B. US women physicians' residential radon testing practices. Am J Prev Med 15 1 (1998) 49-53
5. Barr R., Feeny D., and Furlong W. Economic evaluation of treatments for cancer in childhood. Eur J Cancer 40 9 (2004) 1335-1345
6. Bradley E.J. Responses to radon remediation advice. Proc. 9th Int. Congress International Radiation Protection Association (1996) 4-798-4-800
7. Briggs D.J., Denman A.R., Gulliver J., Marley R.F., Kennedy C.A., Phillips P.S., et al. Time-activity modelling of domestic exposures to radon. J Environ Manag 67 2 (2003) 107-120
8. Clegg A., Scott D.A., Sidhu M., Hewitson P., and Waugh N. Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer: a systematic review. Thorax 57 1 (2002) 20-28
9. Cohen B. Problems in the radon vs. lung cancer test of the linear no-threshold theory and a procedure for resolving them. Health Phys 68 2 (1997) 157-174
10. Coskeran T., Denman A.R., Phillips P.S., and Gillmore G. A critical comparison of the cost-effectiveness of domestic radon remediation programmes in three counties of England. J Environ Radioact 62 (2002) 129-144
11. Coskeran T., Denman A.R., Phillips PS P.S., and Tornberg R. A cost-effectiveness analysis of domestic radon remediation in four Primary Care Trusts located in Northamptonshire, UK. Health Policy 71 1 (2005) 43-56
12. Darby S., Whitley E., Silcocks P., Thakrar B., Green M., Lomas P., et al. Risk of lung lancer associated with residential radon exposure in south-west England: a case-control study. Br J Cancer 78 (1998) 394-408
13. Darby S., Hill R., and Doll R. Radon: a likely carcinogen at all exposures. Ann Oncol 12 (2002) 1341-1451
14. Denman A.R., and Phillips P.S. A review of the cost effectiveness of radon mitigation in domestic properties in Northamptonshire. J Radiol Prot 18 (1998) 119-124
15. Denman A.R., Eatough J.P., Gillmore G., and Phillips P.S. Assessment of health risks to skin and lung from elevated levels in abandoned mines. Health Phys 85 6 (2003) 733-739
16. Denman A.R., Phillips P.S., Tornberg R., and Groves-Kirby C.J. Analysis of the individual health benefits accruing from a domestic radon remediation programme. J Environ Radioact 79 1 (2005) 7-23
17. Department of Health. Health survey for England 1996 (1998), Stationery Office, London
18. Eeckhoudt L.R., and Hammitt J.K. Background risks and the value of a statistical life. J Risk Uncertain 24 (2001) 231-249
19. Ferrer-i-Carbonell A., and van Praag B. The subjective costs of health losses due to chronic diseases: an alternative model for monetary appraisal. Health Econ 11 (2002) 709-722
20. Fiscella K., and Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. J Am Med Assoc 275 16 (1996) 1247-1251
21. Ford E., Kelly A., Teutsch S., Thacker S., and Garbe P. Radon and lung cancer: a cost-effectiveness analysis. Am J Public Health 89 3 (1999) 351-357
22. Gillmore G.K., Sperrin M., Phillips P.S., and Denman A.R. Radon-prone geological formations and implications for cave users. Technology 7 (2000) 645-655
23. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, Oxford
24. Green B.M.R., Miles J.C.H., Bradley E.J., and Rees D.M. Radon atlas of England and Wales. Chilton, National Radiological Protection Board report W26 (2002)
25. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ 12 12 (2003) 1049-1060
26. Health Development Agency. Cancer prevention: a resource to support local action in delivering the NHS cancer plan (2002), HDA, London
27. Health Technology Assessment. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review vol. 5 number 13 (2001) 73 pp.
28. Health Technology Assessment. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review vol. 5 number 2 (2001) 97 pp.
29. Her Majesty's Treasury. The green book: appraisal and evaluation in central government (2003), The Stationery Office, London 114 pp.
30. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., and Weissert W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Mak 20 (2001) 332-342
31. Kennedy C.A., Gray A.M., Denman A.R., and Phillips P.S. A cost effectiveness analysis of a residential radon remediation programme in the United Kingdom. Br J Cancer 81 (1999) 243-247
32. Kip Viscusi W. The value of risks to life and health. J Econ Lit 31 4 (1993) 1912-1946
33. Kreienbrock L., Kreuzer M., Gerken M., Dingerkus G., Wellmann J., Keller G., et al. Case-control study on lung-cancer and residential radon in western Germany. Am J Epidemiol 153 (2001) 42-52
34. Lubin J., and Boice J.D. Lung cancer risk from residential radon: a meta-analysis of eight epidemiological studies. J Natl Cancer Inst 89 1 (1997) 49-57
35. Marshall D., Simpson K.N., Earle C.C., and Chu C.-W. Economic decision analysis model of screening for lung cancer. Eur J Cancer 37 (2001) 1759-1767
36. Mason J., Drummond M., and Torrance G. Some guidelines on the use of cost-effectiveness league tables. Br Med J 306 6877 (1993) 570-572
37. Monthly Digest of Statistics. July 2004, section 18.2 (2004), Stationery Office, London
38. National Radiological Protection Board. Estimates of late radiation risks to the UK population. Documents of the NRPB vol. 4(4) (1993), Chilton, UK
39. Peterson M. Two models for assessing environmental health policy: the case of radon in U.S. homes. Manage Sci 42 (1996) 1476-1492
40. Pinel J., Fearn T., Darby S.C., and Miles J.C.H. Seasonal correction factors for indoor radon measurements in the United Kingdom. Radiat Prot Dosim 58 (1995) 127-132
41. Radon Council. The radon manual. Second Edition (1996), The Radon Council, London
42. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323 (2001) 1300-1303
43. Scuffman P.A., and Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. Pharmacoeconomics 22 8 (2004) 525-535
44. Stigum H., Strand T., and Magnus P. Should radon be reduced in homes? A cost-effectiveness analysis. Health Phys 84 2 (2003) 227-235
45. Sundal A.V., Henriksen H., Soldal O., and Strand T. The influence of geological factors on indoor concentrations of radon in Norway. Sci Total Environ 328 (2004) 41-53
46. Sutherland D., and Sharman G. Radon-in Northamptonshire?. Geol Today 12 2 (1996) 63
47. Thomas A., and Hobson J. Review and evaluation of the radon remediation pilot programme. Department of the Environment, Transport and the Regions Report no. DETR/RAS/00.004, London (2000)
48. Trippoli S., Vaiani M., Lucioni C., and Messori A. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 19 8 (2001) 855-863
49. Warner K.E., Courant P.N., and Mendez D. Effects of residential mobility on individual versus population risk of radon-related lung cancer. Environ Health Perspect 103 12 (1995) 1144-1149
50. Warner K.E., Mendez D., and Courant P.N. Towards a more realistic appraisal of the lung cancer risk from radon: the effects of residential mobility. Am J Public Health 86 9 (1996) 1222-1227
51. Whitehead T.H., Anderson W., Wilson V., and Wray D.A. The Mesozoic ironstones of England. The Liassic ironstones. Memoirs of the geological survey of Great Britain (1952), HMSO, London (with contributions by K.C. Dunham)
52. Williams A. What could be nicer than NICE? (2004), Office of Health Economics Annual Lecture
53. Wrixon A.D., Green B.M.R., Lomas P.R., Miles J.C.H., Cliff K.D., Francis E.A., et al. Natural radiation exposure in UK dwellings report NRPB-R190 (1988), National Radiological Protection Board, Didcot
54. Wysocka M. Geophysical methods of supporting radon risk mapping. ERRICCA 2, Dublin meeting, 19th-20th May 2003. Geological survey of Ireland (2003)